High Prevalence of Chronic Disease Such as Kidney around the Globe Is Driving the Growth of the Ioversol Market

 

Ioversol, otherwise called IOU peroxide, can be used as a dialysis anticoagulant in hospitals for treating dialysis patients and can be used commercially for treating toothache. It is an oxidizing agent for internal applications in the human body. The Ioversol chemical name is Isoflavones and contains seven carbon atoms with one hydrogen atom in accordance with many substances derived from plants (Isoflavones). Isoflavones are commonly within fruits such as strawberry and lemon, and also in egg yolk and some vegetables, notably artichokes, parsley, beets, carrots, leek, and kidney beans. Ioversol (Iodine-Orient-containing Nutrient suspension) is generally used for the relief of inflammation and to deal with infections, to avoid or reduce bleeding, as dialysis therapy and to boost blood flow and oxygenate blood

The growing prevalence of bone-related disorders is a leading factor driving the growth of the Ioversol Market. Increasing geriatric population around the world which is increasing the prevalence of the different chronic disease. This has raised the demand for a different diagnostic tool such as X-ray which is another key factor fueling the growth of the market. In line with the United Nation, by 2050, one in six people on the planet is going to be over age 65 (16%), up in one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could possibly be aged 65 or over. The rise in spending on the healthcare sector by government for improving the in-patient care is further anticipated to propel the growth of the ioversol market.

North America is projected to get significant growth over the forecast period and this is attributed to the high prevalence of the bone-related disorder in the region which. In 2017, the amount of Canadians afflicted with osteoporosis had increased to 2 million. By the entire year 2030, the amount of hip fractures is likely to quadruple. Moreover, In Canadians of 40 years or older, 1.5 million (10%) reported having been diagnosed with osteoporosis. Thus the high prevalence of bone a related disorder is projected to foster the growth of the ioversol market.

Key Developments:

In December 2020, Guerbet (GBT), a worldwide provider of medical imaging, announced so it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) (Ioversol Injection) in the United States.